Novartis AG (NVZ, Switzerland)
Novartis is a Swiss pharmaceutical company that was formed when Ciba-Geigy and Sandoz merged in 1996. Novartis produces several well-known drugs including Clozaril, Ritalin, and Voltaren. It also produces several products for the pet care and agriculture industries.
In total, the company owns patents on over one hundred pharmaceuticals, with several more in development. In fact, ten Novartis products have sales of over $100 million a month. Positive results were recently announced for tests of a breast cancer drug the company is developing.
The company’s market cap of CHF 231 billion with annual sales over CHF 50 billion. Novartis is currently fairly valued but is a defensive company and a solid long-term investment.
All content is provided for your information only.
This article may contain opinions and is not advice or a recommendation to buy, sell or hold any investment. No representation or warranty is given on the present or future value or price of any investment, and investors should form their own view on any proposed investment. This article has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is considered a marketing communication. Non-independent research is not subject to FCA rules prohibiting dealing ahead of research, however we have put controls in place (including dealing restrictions, physical and information barriers) to manage potential conflicts of interest presented by such dealing.
One Financial Markets expressly disclaims all liability from actions or transactions arising out of the usage of this content. By using our services, you expressly agree to hold One Financial Markets harmless against any claims whatsoever and confirm that your actions are at your sole discretion and risk.